Use of a composition made of mineral nutrients and optionally acetogenic and/or butyrogenic bacteria in order to avoid or reduce the formation of gas in the large intestine of a mammal and the resulting abdominal problems

Use of a composition comprising tungsten and/or a tungsten compound for the administration to a mammal for the manufacture of a medicament for the prevention or reduction of gas formation in the colon and thus conditioned abdominal complaints, particularly bloatings, meteorism or abdominal cramps.

Use according to any preceding claim, characterized in that the composition further contains one or more strains of acetogenic bacteria.

Use according to claim 7, characterized in that at least one acetogenic bacterial strain is selected from the group consisting of:

• Ruminococcus, Eubacterium, Clostridium, or a strain isolated by a method according to claims 45 to 48

Use according to any preceding claim, characterized in that the composition further contains one or more strains of butyrogenic bacteria.

Use according to claim 10, characterized in that at least one strain of butyrogenic bacteria is selected from the group consisting of:

• Fusobacterium, Faecalibacterium, Eubacterium, Clostridium, or a strain isolated by a method according to claims 41 to 44

Use according to any of the previous claims, characterized in that the composition also contains vanadium, nickel, iron, sodium, potassium.

Use according to any of the previous claims, characterized in that the composition also contains vitamins, especially vitamin A, vitamin B, vitamin C, vitamin D, vitamin E, vitamin K.

Use according to any preceding claim, characterized in that the composition additionally contains one or more nitrogen containing compounds and/or carbohydrate compounds, preferably poorly absorbed by the small intestine of the mammal.

Use according to any preceding claim, characterized in that the composition is gradually released in the colon over a period of at least 3 hours, preferably 6 hours, more preferably 12 hours.

Use according to any preceding claim, characterized in that the abdominal symptoms are caused by at least one of the following gastrointestinal disorders:

• fructose malabsorption, fructose intolerance, lactose intolerance, irritated bowel syndrome, lack of disaccharase, lack of trehalase, short bowel syndrome, irritable bowel syndrome, bloating, meteorism, diarrhea, crohn's disease, three month colic, exocrine pancreatic insufficiency, bile acid deficiency, gastric acid deficiency, dysbiosis of the intestinal flora caused by antibiotics, lack of acetogenic bacteria, lack of reductive acetogenic metabolic function of the intestinal flora, celiac disease, sprue, gluten intolerance, histamine intolerance.

Use according to any preceding claim, characterized in that the composition contains further enterobacteriaceae, preferably of the species Escherichia coli, either in a separate or the same pharmaceutical preparation, whereas the medicament is instead, and/or additionally designed for the treatment of diarrhea.

Use according to any preceding claims, characterized in that the drug instead and/or additionally earmarked to support the reconstruction and regeneration of the intestinal flora and their acetogenic metabolic function subsequent to an antibiotic treatment, hydro-colon therapy and colonic lavages or gastrointestinal infections.

Use according to any preceding claim, characterized in that the administration is orally or rectally.

Use according to any preceding claim, characterized in that the mammal is human.

Composition comprising one or more minerals selected from the group consisting of selenium, molybdenum or tungsten, which is carried out galenically or chemically in a way that the mineral or minerals are released completely or in part, just before, during or shortly after arrival at the colon, for the administration to a mammal for the prevention or reduction of gas formation in the colon and thus conditioned abdominal complaints, particularly bloatings, meteorism or abdominal cramps.

Composition comprising tungsten and/or a tungsten containing compound for the administration to a mammal for the prevention or reduction of gas formation in the colon and thus conditioned abdominal complaints, particularly bloatings, meteorism or abdominal cramps.

Composition according to claim 27, characterized in that at least one acetogenic bacterial strain is selected from the group consisting of:

• Ruminococcus, Eubacterium, Clostridium, or a strain isolated by a method according to claims 45 to 48

Composition according to claim 30, characterized in that at least one strain of butyrogenic bacteria is selected from the group consisting of:

• Fusobacterium, Faecalibacterium, Eubacterium, Clostridium, or a strain isolated by a method according to claims 41 to 44

Procedure for the isolation of butyrogenic bacteria from the feces of a mammal comprising the steps:

• creating a culture of bacteria from feces samples of an individual in a suitable culture medium containing as the sole energy and carbon source acetic acid.

Procedure according to any of the preceding claims, characterized in that the growth medium is an anaerobic nutrient medium.

Procedure according to any of the preceding claims, characterized in that the nutrient medium also contains an acetic acid indicator.

Procedure according to any of the preceding claims, characterized in that feces from asymptomatic individuals are used for the isolation.

Procedure for isolating acetogenic bacteria from the feces of a mammal comprising the steps:

• creating a culture of bacteria from feces samples of an individual in a suitable culture medium containing as the sole energy and carbon source H2 and CO2.

Procedure according to any of the preceding claims, characterized in that the nutrient medium also contains an acetic acid indicator.

Procedure according to any of the preceding claims, characterized in that feces from asymptomatic individuals are used for the isolation.